Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas. The company’s most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn’s disease. In 2016 the company downsized and shifted its focus to developing new drugs currently being tested in clinical trials.

Cognosci Inc. was founded in May 2000 to develop anti-inflammatory compounds for the treatment of neuroinflammatory diseases including Multiple Sclerosis, Alzheimer's Disease, and brain bleeding events. Each of these disorders has a pharmacogenomic linkage to the apolipoprotein E (APOE) protein and patients with the APOE-ε4 allele typically suffer worse outcomes. Based on these findings, scientists from Duke University created a novel APOE-based compound that had potent anti-inflammatory and neuroprotective activities.

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

American Cyanamid Company was a U.S.-based diversified company with businesses in several fields. The company was a manufacturer of agricultural chemicals, cosmetics, perfumes, building products, plastics and pharmaceuticals. The company was listed as a top 100 manufacturing company by Fortune magazine in the 1970s. Cyanamid was founded in 1907 and employed over 100,000 people around the world by 2000. The company maintained a monopoly over tetracycline, an antibiotic used against bacterial infections. A theft of the organism led to the loss of the monopoly as rival companies were able to produce generic versions of the formula, leading to huge losses to the company. The company sold most of its businesses in the early 2000s and is now operated under the name Cytec.  

Marudai Food Co., Ltd. engages in the food business. It operates through the following segments: Processed Food, Meat Products, and Others. The Processed Food segment manufactures and sells hams, sausages, and cooked and processed food products. The Meat Product segment deals with purchasing, processing and sale of meat products. The Others segment provides insurance services. The company was founded by Toshiyuki Komori in 1954 and is headquartered in Osaka, Japan.

Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

Kangshi Pharmaceutical Technology (Shanghai) Co., Ltd., established on 2015-12-15, Business scope includes biological products,Research and development of pharmaceutical products and pharmaceutical intermediates(remove human stem cells,Development and application of genetic diagnosis and treatment technology),Provide relevant technical consultation and technical services,Transfer of own technological achievements,Chemical raw materials and products(In addition to dangerous goods),Instrumentation,Wholesale of electronic products,import and export,commission agent(except auction),and provide related services(Commodities that do not involve state trade management,Quota involved,of license-managed goods,Apply in accordance with relevant national regulations).[Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

G��deke GmbH is a German private company located in Dassel that operates as sawmills. The firm was founded in 1981. Torsten G��deke is the current CEO of the firm.

Celtrix is a biopharmaceutical company focused on developing novel therapeutics for the treatment of seriously debilitating, degenerative conditions primarily associated with severe trauma, chronic diseases or aging.

Arizona Board of Regents oversees college activities. The company was founded in 1864 and is headquartered in Phoenix, AZ.

Hangzhou Puyuan Biotechnology Co., Ltd., established on 2021-04-08, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Information Consulting Service(Not including licensing information consulting services);Natural science research and experimental development;Medical Research and Experimental Development;Research and development of bio-based materials technology;R&D and application of cell technology;Fermentation process optimization technology research and development;Bio-feed R&D;Research and development of compound microbial fertilizer;R&D of industrial enzyme preparations;Health Supplies(non food)Production;Manufacturing of special instruments;Maternal and baby products manufacturing;Personal Internet Live Streaming Service;sales agent;internet sales(Except for products that require a license for sale);Instrument sales;Drug testing equipment sales;Sales of Class I Medical Devices;Health Supplies(non food)Sales;Food Additive Sales;Feed Additive Sales;Pet Food and Supplies Wholesale;Pet food and supplies retail;Wholesale of edible agricultural products;Retailing of Edible Agricultural Products;Food import and export;Import and export;Technology Import and Export(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:food production;beverage production;dairy production;Infant formula production;Health food production;Production of formula food for special medical purpose;Food additive production;Feed additive production;pharmaceutical production;Pharmaceutical commissioned production;Production of Class II Medical Devices;Production of Class III Medical Devices;food sales;Food Internet Sales;Drug Wholesale;Drug retail;Class III medical device business;Internet live broadcast technology service;Import and export of edible fungi;Drug import and export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Tianjin Medical University General Hospital (Chinese: 天津医科大学总医院) is a general hospital in the central Heping District of the Chinese metropolis of Tianjin, associated with Tianjin Medical University.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Encysive Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes synthetic and small molecule compounds to address medical needs worldwide. The company focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade, and vascular diseases. Its products include Argatroban for the treatment of heparin-induced thrombocytopenia; and Thelin (sitaxsentan sodium), an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, congestive heart failure, and essential hypertension. The company's clinical development compounds include TBC3711, an endothelin receptor antagonist; TBC4746, an antigen-4 antagonist; ENC8003, a G protein-coupled receptor; and bimosiamose, a selectin antagonist. Encysive Pharmaceuticals has research collaboration and license agreements with GlaxoSmithKline plc; Mitsubishi Pharma Corporation; Schering-Plough, Ltd.; Schering Corporation; and Revotar Biopharmaceuticals, AG. The company was founded in 1989. It was formerly known as Texas Biotechnology Corporation and changed its name to Encysive Pharmaceuticals, Inc. in 2003. Encysive Pharmaceuticals is based in Houston, Texas. As of June 10, 2008, Encysive Pharmaceuticals Inc. operates as a subsidiary of Pfizer Inc.

Phlogo ApS, a subsidiary of Serodus ASA, is a company headquartered in Hellerup, Denmark, that manufactures pharmaceutical products. The firm was acquired by Serodus ASA on July 10, 2013.

The American Can Company was a manufacturer of tin cans. It was a member of the Tin Can Trust, that controlled a "large percentage of business in the United States in tin cans, containers, and packages of tin." American Can Company ranked 97th among United States corporations in the value of World War II military production contracts. It was formerly a member of the Dow Jones Industrial Average from 1959–1991, though after 1987 it had renamed itself Primerica, a financial conglomerate which had divested itself of its packaging arm in 1986.

National Cancer Center Korea is a South Korean company located in Goyang-si and ultimately controlled by the Government of South Korea. The firm provides clinical and medical research services.